TrueBinding, Inc.
TrueBinding Inc. is a clinical stage biotherapeutic company dedicated to creating innovative molecules for neurodegenerative and metabolic diseases, stroke, oncology, and other areas with unmet medical needs. They focus on developing targeted monoclonal antibody therapeutics using their proprietary TrueBinding™ platform technology, aiming to improve patient outcomes through precision medicine. The company also offers contract development and manufacturing services to accelerate biopharmaceutical innovation.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
TB006 (investigational monoclonal antibody targeting Galectin-3)
A humanized monoclonal antibody designed to bind and neutralize Galectin-3 to inhibit aggregation of amyloid-beta and reduce neuroinflammation; advanced through preclinical models and early-phase clinical trials with imaging and biomarker endpoints.
TB006 (investigational monoclonal antibody targeting Galectin-3)
A humanized monoclonal antibody designed to bind and neutralize Galectin-3 to inhibit aggregation of amyloid-beta and reduce neuroinflammation; advanced through preclinical models and early-phase clinical trials with imaging and biomarker endpoints.
Services
CDMO-style services covering development, CMC-related activities, and GMP-aligned bioprocessing to support antibody production and scale-up for clinical programs.
CDMO-style services covering development, CMC-related activities, and GMP-aligned bioprocessing to support antibody production and scale-up for clinical programs.
Expertise Areas
- Monoclonal antibody therapeutics
- Target discovery and validation
- Preclinical neurodegenerative disease models
- Clinical trial management (Phase 1–2)
Key Technologies
- Monoclonal antibody engineering and humanization
- Target/ligand identification platforms
- Transgenic AD animal models (e.g., APPSwe, 5xFAD)
- PET and MRI neuroimaging
News & Updates
On April 23, 2021, the FDA granted clearance for the clinical development of TB006 for Alzheimer's Disease, aiming to reduce amyloid-β and tau protein aggregation and mitigate neuroinflammation.
Topline data from a one-month TB006 treatment regimen shows improvements in cognition and function, indicating potential to slow or reduce clinical decline.
The FDA approved TrueBinding to proceed with clinical trials for TB006 in treating adult autism spectrum disorder.
The FDA renewed the Expanded Access Program for TB006, allowing continued compassionate use for patients with dementia and Alzheimer’s.
TrueBinding cleared an IND application for TB006 for potential disease modification of Parkinson’s Disease, with a Phase 2A trial evaluating safety and efficacy.
Early clinical trials indicate TB006 can improve cognition and potentially reverse Alzheimer’s disease progression.
On April 23, 2021, the FDA granted clearance for the clinical development of TB006 for Alzheimer's Disease, aiming to reduce amyloid-β and tau protein aggregation and mitigate neuroinflammation.
Topline data from a one-month TB006 treatment regimen shows improvements in cognition and function, indicating potential to slow or reduce clinical decline.
The FDA approved TrueBinding to proceed with clinical trials for TB006 in treating adult autism spectrum disorder.
The FDA renewed the Expanded Access Program for TB006, allowing continued compassionate use for patients with dementia and Alzheimer’s.
TrueBinding cleared an IND application for TB006 for potential disease modification of Parkinson’s Disease, with a Phase 2A trial evaluating safety and efficacy.
Early clinical trials indicate TB006 can improve cognition and potentially reverse Alzheimer’s disease progression.